Imugene Limited

The replay of our April 2025 Investor Update & FAQ Webinar is now available. Executive Chairman Paul Hopper, Managing Director & CEO Leslie Chong and Chief Operating Officer Brad Glover responded to shareholder questions and provided updates across Imugene’s programs. Watch the full session here: https://lnkd.in/gMuC65U8 #Imugene #IMU #InvestorUpdate #Biotech #ClinicalTrials #Immunotherapy #CancerResearch #FAQWebinar

REMINDER | Tomorrow, we're hosting a webinar for shareholders, investors, and anyone interested to share the latest company updates and answer some of the most frequently asked questions. The webinar will be hosted by Executive Chairman Paul Hopper, and he will be joined by CEO & Managing Director Leslie Chong and Chief Operating Officer Brad Glover. The webinar will be held at 11:00am AEST (Wednesday, 16 April 2025). Shareholders, investors and interested parties can register to attend the webinar at the following link: https://lnkd.in/gMuC65U8 Shareholders are encouraged to submit questions for the webinar in advance via email at: shareholderenquiries@imugene.com A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via our website and social media channels.  #IMU #Imugene #Biotech #ASX

Imugene’s Senior Director, Translational Research, Grey A. Wilkinson, presented our poster 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑜𝑓 𝐶ℎ𝑜𝑙𝑎𝑛𝑔𝑖𝑜𝑐𝑎𝑟𝑐𝑖𝑛𝑜𝑚𝑎 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑂𝑛𝑐𝑜𝑙𝑦𝑡𝑖𝑐 𝑉𝑖𝑟𝑢𝑠 𝐶𝐹33-ℎ𝑁𝐼𝑆 yesterday at the 2025 Cholangiocarcinoma Foundation Annual Conference (CFAC) in Salt Lake City, Utah. #IMU #Imugene #CFAC2025 #Cholangiocarcinoma #CF33 #OncolyticVirus #Immunotherapy #Imugene #CancerResearch

We're hosting a webinar for shareholders, investors, and anyone interested to share the latest company updates and answer some of the most frequently asked questions. The webinar will be hosted by Executive Chairman Paul Hopper, and he will be joined by CEO & Managing Director Leslie Chong and Chief Operating Officer Brad Glover. The webinar will be held at 11:00 am AEST on Wednesday, 16 April 2025. Shareholders, investors and interested parties can register to attend the webinar at the following link: https://lnkd.in/gMuC65U8 Shareholders are encouraged to submit questions for the webinar in advance via email at: shareholderenquiries@imugene.com. A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via our website and social media channels.  #IMU #Imugene #Biotech #ASX #smallcaps

Imugene Limited has cleared the first dose level in the intravenous (IV) combination arm of its Phase 1 onCARlytics #clinicaltrial, following Cohort Review Committee (CRC) approval. The OASIS study targets adult #patients with advanced or metastatic solid tumours and will now proceed to a higher dose level as part of its planned escalation process. This first-in-human trial aims to induce CD19 expression in solid tumours using onCARlytics, an oncolytic virus, thereby making the tumours susceptible to CD19-directed #immunotherapies. The OASIS trial is assessing two administration routes—intratumoural (IT) and intravenous (IV)—of onCARlytics, both alone and in combination with the CD19-targeting bispecific monoclonal antibody blinatumomab (Blincyto®). More at http://ow.ly/h5lG1064tbS #Proactive #ProactiveInvestors #ASX #Oncology #CancerResearch #Biotech

We've cleared the first dose level in the intravenous (IV) combination arm of our Phase 1 onCARlytics trial. The study, known as OASIS, is targeting adult patients with advanced or metastatic solid tumours and is evaluating the safety and efficacy of intravenous and intratumoural administration of either onCARlytics (a CD19-expressing oncolytic virus) alone or in combination with CD19 targeting bispecific monoclonal antibody blinatumomab (Blincyto®), which is a cancer immunotherapy. Dose escalation will continue as we advance towards full recruitment of 40-50 patients across U.S. trial sites. Managing Director and Chief Executive Officer Leslie Chong, said: “CD19 is a very significant target for blood cancers, but solid cancers like breast, lung or gastric do not have a common target on their cell surface, and therefore the aim with onCARlytics is to make available a target for CD19 therapies to treat these solid cancers. As the trial continues to progress and dose escalation is executed, we are eager to learn of the potential impact our treatment is having for patients in need.” Read the full ASX Announcement: https://lnkd.in/gded4C3D #Imugene #onCARlytics #CD19 #Immunotherapy #ASX #CancerResearch #DLBCL #SolidTumours #Biotech #OASISTrial #IMU

𝗠𝗲𝗲𝘁 𝗦𝗵𝗮𝗿𝗼𝗻 𝗬𝗮𝘃𝗿𝗼𝗺 – 𝗘𝘅𝗲𝗰𝘂𝘁𝗶𝘃𝗲 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿, 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝘁 𝗜𝗺𝘂𝗴𝗲𝗻𝗲 Sharon brings extensive experience in oncology drug development, having contributed to therapies like Yervoy, Nivolumab, Nerlynx, and XGEVA. She has worked across academia and industry, earning a Ph.D. in pathology and focusing on treatments for lung cancer, glioblastoma, breast cancer, Ewing’s sarcoma, and lymphomas. Since joining Imugene nearly three years ago, Sharon has played a key role across all clinical programs, shaping study designs, supporting publications, and driving trial execution. She now focuses on azer-cel, where she has developed expertise in cell therapy. Sharon is particularly excited about azer-cel’s IL-2 cohort data, which shows promise in improving CAR-T expansion and persistence, potentially redefining allogeneic CAR-T treatment. As Executive Director of Clinical Science, Sharon helps guide Imugene’s clinical programs from design through to execution, ensuring trials progress. #MeetTheTeam #ClinicalResearch #CAR_T #Immunotherapy #Imugene #IMU #Leadership #Oncology #ClinicalDevelopment Sharon Yavrom, Ph.D.

📣 We're excited to share our March newsletter. This edition includes updates on our key clinical milestones for azer-cel, recent intellectual property milestones, and highlights from our latest Q&A sessions. We also welcome our new CFO, Darren Keamy, and highlight recent media coverage and presentations. Read more: https://lnkd.in/gZtFEXkA #Imugene #IMU #Biotech #CancerResearch #Immunotherapy #CAR_T #OncolyticVirus #MedicalInnovation

In case you missed it – CEO & Managing Director Leslie Chong's presentation at the NWR Communications Healthcare Conference is now available to watch. 🎥 Watch the replay here: https://lnkd.in/gC5vt6H4 #IMU #Imugene #Biotech #ASX #Healthcare

Our CEO & Managing Director Leslie Chong joins Proactive to discuss the FDA’s Fast Track Designation for azer-cel, our allogeneic CAR T-cell therapy for relapsed/refractory DLBCL. With promising response rates and a growing clinical program, this designation supports expedited development for patients with high unmet need. 📺 Watch the full interview here: https://lnkd.in/g4H4Uekm #Imugene #IMU #Biotech #CancerResearch #CAR_T #FDA #FastTrack #DLBCL #Immunotherapy #BloodCancer #MedicalInnovation #Oncology Kerry Stevenson